Ruxolitinib in myelofibrosis and baseline thrombocytopenia in real-life: results in Dutch patients and review of literature

ConclusionRuxolitinib treatment appears to be safe for patients with platelet counts of 50-100x109/l, also in real-life practice. We did not find any reason to discourage a starting dose of 10mg BID in this subgroup.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research